M-1095
As of the edition of 20 October 2026, M-1095 is a drug: in active development; acts on IL17A and IL17F.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Unknown
- Registered trials
- 12, 0 stopped early
- Disease areas
- Skin and connective tissue; Infections; Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 7 | 2 | 5 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2014 to now |
| Bond Avillion | Lead sponsor of trials | 2018 to now |
| MoonLake Immunotherapeutics | Lead sponsor of trials | 2022 to now |